These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 26244757

  • 1. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
    Azaïs H, Queniat G, Bonner C, Kerdraon O, Tardivel M, Jetpisbayeva G, Frochot C, Betrouni N, Collinet P, Mordon S.
    Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
    Azaïs H, Schmitt C, Tardivel M, Kerdraon O, Stallivieri A, Frochot C, Betrouni N, Collinet P, Mordon S.
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
    [Abstract] [Full Text] [Related]

  • 3. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
    Azaïs H, Frochot C, Grabarz A, Khodja Bach S, Colombeau L, Delhem N, Mordon S, Collinet P.
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
    [Abstract] [Full Text] [Related]

  • 4. [FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?].
    Azaïs H, Moussaron A, Khodja Bach S, Bassil A, Betrouni N, Frochot C, Collinet P, Mordon S.
    Bull Cancer; 2014 Dec; 101(12):1109-13. PubMed ID: 25532689
    [Abstract] [Full Text] [Related]

  • 5. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.
    Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A, Matherly LH.
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Intraperitoneal photodynamic therapy for peritoneal metastasis of epithelial ovarian cancer. Limits and future prospects].
    Azaïs H, Mordon S, Collinet P.
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):249-256. PubMed ID: 28373041
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R.
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [Abstract] [Full Text] [Related]

  • 11. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH, Boerman OC, Bos DL, Massuger LFAG, Weil S, Grasso L, Rybinski KA, Oosterwijk E, Mulders PFA, Rijpkema M.
    Mol Pharm; 2017 Oct 02; 14(10):3457-3463. PubMed ID: 28826214
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeted Photodynamic Therapy using a Vectorized Photosensitizer coupled to Folic Acid Analog induces Ovarian Tumor Cell Death and inhibits IL-6-mediated Inflammation.
    Boidin L, Moinard M, Moussaron A, Merlier M, Moralès O, Grolez GP, Baydoun M, Mohd-Gazzali A, Tazizi MHDM, Allah HHA, Kerbage Y, Arnoux P, Acherar S, Frochot C, Delhem N.
    J Control Release; 2024 Jul 02; 371():351-370. PubMed ID: 38789088
    [Abstract] [Full Text] [Related]

  • 16. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N, Chen J, Li T, Liu W, Liu J, Chen H, Wang J, Jia L.
    Mol Carcinog; 2017 Aug 02; 56(8):1896-1908. PubMed ID: 28277622
    [Abstract] [Full Text] [Related]

  • 17. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
    Wang ZQ, Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Guillemette C, Gobeil S, Macdonald E, Vanderhyden B, Bachvarov D.
    Oncotarget; 2015 Oct 13; 6(31):31522-43. PubMed ID: 26372729
    [Abstract] [Full Text] [Related]

  • 18. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
    Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, O'Shannessy DJ, Somers EB, Vergote I.
    Gynecol Oncol; 2013 Jul 13; 130(1):192-9. PubMed ID: 23558051
    [Abstract] [Full Text] [Related]

  • 19. The folate receptor as a rational therapeutic target for personalized cancer treatment.
    Assaraf YG, Leamon CP, Reddy JA.
    Drug Resist Updat; 2014 Jul 13; 17(4-6):89-95. PubMed ID: 25457975
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.
    Clin Cancer Res; 2015 Jan 15; 21(2):448-59. PubMed ID: 25416196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.